These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Systemic therapy for ovarian cancer: current status and new treatments. Ozols RF Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797 [TBL] [Abstract][Full Text] [Related]
24. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study. Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766 [TBL] [Abstract][Full Text] [Related]
25. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents. Ozols RF J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247 [TBL] [Abstract][Full Text] [Related]
26. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Takakura S; Takano M; Takahashi F; Saito T; Aoki D; Inaba N; Noda K; Sugiyama T; Ochiai K; Int J Gynecol Cancer; 2010 Feb; 20(2):240-7. PubMed ID: 20169667 [TBL] [Abstract][Full Text] [Related]
27. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. Dizon DS; Dupont J; Anderson S; Sabbatini P; Hummer A; Aghajanian C; Spriggs D Gynecol Oncol; 2003 Dec; 91(3):584-90. PubMed ID: 14675681 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Power P; Stuart G; Oza A; Provencher D; Bentley JR; Miller WH; Pouliot JF Gynecol Oncol; 2009 Sep; 114(3):410-4. PubMed ID: 19520420 [TBL] [Abstract][Full Text] [Related]
29. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer. Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048 [TBL] [Abstract][Full Text] [Related]
30. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. International Collaborative Ovarian Neoplasm Group Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653 [TBL] [Abstract][Full Text] [Related]
31. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage. Ljuca D; Fatusić Z; Iljazović E; Ahmetović B Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744 [TBL] [Abstract][Full Text] [Related]
32. Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma. Takai N; Utsunomiya H; Kawano Y; Nasu K; Narahara H; Miyakawa I Arch Gynecol Obstet; 2002 Dec; 267(2):98-100. PubMed ID: 12439556 [TBL] [Abstract][Full Text] [Related]
33. Chemotherapy for ovarian cancer: an evidence-based approach. Geisler JP; Manahan KJ; Wiemann MC Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206 [TBL] [Abstract][Full Text] [Related]
34. [A case of neo-JP therapy in the treatment of ovarian carcinoma]. Matsunami K; Takagi H; Hasegawa Y Gan To Kagaku Ryoho; 1995 Jan; 22(1):153-5. PubMed ID: 7826073 [No Abstract] [Full Text] [Related]
35. Increasing the chances for platinum-sensitive ovarian cancer patients. González A Future Oncol; 2013 Dec; 9(12 Suppl):29-35. PubMed ID: 24195528 [TBL] [Abstract][Full Text] [Related]
36. Clear-cell cancer of the ovary-is it chemosensitive? Pather S; Quinn MA Int J Gynecol Cancer; 2005; 15(3):432-7. PubMed ID: 15882166 [TBL] [Abstract][Full Text] [Related]
37. Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum. Hsiao SM; Chen CA; Lin HH; Hsieh CY; Wei LH Gynecol Oncol; 2009 Jan; 112(1):35-9. PubMed ID: 18977021 [TBL] [Abstract][Full Text] [Related]
38. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin. Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319 [TBL] [Abstract][Full Text] [Related]
39. Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients. Molckovsky A; Vijay SM; Hopman WM; Bryson P; Jeffrey JF; Biagi JJ Int J Gynecol Cancer; 2008; 18(1):8-13. PubMed ID: 17511802 [TBL] [Abstract][Full Text] [Related]